Copper's a red hot bet for the rest of 2025
Red metal has turned into a hot commodity play, with M&A and big capital raisings showing investors are laser-focused on it
Hillgrove Resources the most undervalued option on the ASX, says Bell Potter
The copper price recently hit US$10,000 per tonne for the first time this year and analysts see further upside in the coming months.
Copper has staged a strong recovery since April, when it dipped to around US$8500/t following the announcement of US President Donald Trump's Liberation Day tariffs.
Last week, Goldman Sachs said the Section 232 investigation into US tariffs was driving an unusually wide gap between COMEX prices in New York and and London Metal Exchange prices, which had resulted in the US 'over-importing' roughly 400,000 tonnes of copper since the start of the year.
'US inventory has risen to over 100 days' worth of consumption, up from just 33 days at the beginning of the year,' the bank said.
'As a result, the ex-US copper market has tightened, causing fears of a regional copper shortage despite the global market being in surplus.
'The front of the LME curve has tightened substantially, with the LME cash contract briefly trading over US$10,000/t on June 23 and has traded at a US$95-379/t premium to the three-month contract week.'
As a result of fears of a shortage outside the US, Goldman Sachs lifted its December 2025 half LME copper price forecast to an average of US$9890/t, a decent uplift from its previous forecast of US$9140/t.
'We expect the copper price to rise to a peak for the year of US$10,050/t in August due to (1) the tariff-driven reduction in ex-US stocks, and (2) China sentiment and activity remaining relatively resilient (for now), before declining to US$9700/t by December,' Goldman said.
'The expected decline reflects our base case (80% probability) of a 25% tariff being put in place on US copper imports by September, but a later than expected tariff implementation could keep LME prices higher for longer.'
'Scramble' is on
Australia's newest copper producer, Bill Beament's Develop Global (ASX:DVP), last week raised $180 million to fuel its copper growth ambitions.
Beament said the level of interest in its now suspended sale process for a minority interest in its Woodlawn mine in New South Wales indicated that a 'scramble' for copper offtake was unfolding.
'It has become increasingly obvious to us that there is a window of lucrative opportunity in the copper and base metals space generally,' he said.
'There is a global race on to secure offtake of these crucial metals, particularly from tier-1 locations, and we are in the box seat to take full advantage of this opportunity.'
That scramble is evident in the bidding war unfolding for New World Resources (ASX:NWC).
After being virtually unloved for most of last year, the copper developer finds itself at the centre of a three-way tussle between AIM-listed Central Asia Metals and US private equity fund Kinterra Capital.
New World's Antler copper project in Arizona has a resource of 11.4 million tonnes at 4.1% copper equivalent, making it one of the highest-grade copper deposits in North America.
Antler has been designated as a Fast-41 Transparency Project by the US government, keeping the project on track for first production in 2027.
At this stage, New World is backing Central Asia's bid, which was increased to 6.2c per share, from the original bid price of 5c per share, trumping Kinterra's 5.7c per share bid.
However, Kinterra holds more than 19% of New World and has made an application to the Takeovers Panel, indicating that there may be more to play out in the saga.
Copper miners making hay
There's still only a handful of copper producers on the ASX and soon to be one less, with MAC Copper (ASX:MAC) set to be snapped up by South Africa's Harmony Gold for US$1.03 billion.
Market leader Sandfire Resources (ASX:SFR) is trading at close to all-time highs, its market capitalisation pushing through $5 billion in the process.
Last week, AIC Mines (ASX:A1M) secured a US$40M prepayment facility linked to an offtake agreement with Trafigura and raised $55 million to fund its new Jericho mine and expand the Eloise plant in Queensland.
According to recent research from Bell Potter Securities, the cheapest ASX-listed copper miner on an enterprise value basis is South Australian producer Hillgrove Resources (ASX:HGO).
Its market cap is less than half of AIC's, despite the two companies having similar production profiles this year.
Hillgrove operates the Kanmantoo underground copper mine in South Australia, where it has been quietly ticking off milestones in its aim to become a mid-tier copper producer.
The mine hit commercial production a year ago and achieved record production of 2952 tonnes of copper in the March quarter, generating $12.7 million of mine operating cashflow.
Earlier this year, Hillgrove raised $18 million to accelerate the development of the Nugent deposit and increase exploration.
That strategy is already paying off, with Hillgrove announcing last week that development rates at Nugent had outperformed expectations, delivering the first development ore 3-6 months ahead of plan.
The Nugent development ore has been delivered to the mill ahead of first stoping ore in the December quarter.
Hillgrove said the early milestone provided operational flexibility ahead of a planned increase in mill throughput from the current 1.4Mt per annum run-rate to 1.7-1.8Mtpa in the first half of next year.
In the meantime, production for the month of June was expected to be slightly lower at 750-800t of copper as the company prioritised development and deferred high-grade stopes.
Hillgrove said the approach would position the company for a stronger, more consistent performance in the second half of the year and beyond.
The company maintained full-year guidance of 12,000-14,000t of copper.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles

ABC News
8 hours ago
- ABC News
NBA approves American record sale of Boston Celtics to private equity mogul Bill Chisholm
The NBA has unanimously approved the sale of the Boston Celtics to a group led by private equity mogul Bill Chisholm, a deal that values the franchise at $9.31 billion (US$6.1 billion). The league said the transaction is expected to close soon. When it does, Chisholm will take ownership of at least 51 per cent of the team, with full control coming by 2028 at a price that could bring the total value to $11.15 billion (US$7.3 billion). That's the largest price ever paid for an American professional sports team, though Los Angeles Dodgers owner Mark Walter has agreed to buy a controlling share of the Lakers in a deal that would place the value of the entire franchise at $15.27 billion (US$10 billion). It's not clear how much Walter would own; current owner Jeanie Buss is expected to retain at least 15 per cent of the team. The previous record for a US sports franchise was the US$6.05 billion paid for the NFL's Washington Commanders in 2023. The record price for an NBA team was the US$4 billion mortgage firm owner Mat Ishbia paid for the Phoenix Suns in 2023. A Massachusetts native and graduate of Dartmouth College and Penn's Wharton School of business, Chisholm is the managing partner of California-based Symphony Technology Group. The new ownership group also includes Boston businessmen Rob Hale, who is a current Celtics shareholder, and Bruce Beal Jr. Wyc Grousbeck led the ownership group that bought the team in 2002 for US$360 million and presided over NBA championships in 2008 and 2024. The franchise's 18 NBA titles is a record. Chisholm outbid at least two other groups, one led by previous Celtics minority partner Steve Pagliuca. Pagliuca has since announced plans to but the WNBA's Connecticut Sun for US$325 million and move them to Boston, but the women's league has baulked at the deal. AP

The Australian
9 hours ago
- The Australian
Argenica brain drug paces for FDA clearance
FDA provides clear path for Argenica to lift clinical hold on its ARG-007 stroke drug Further clarification on safety of dose in humans and three additional in vitro lab studies requested Company confident studies are straightforward and can be completed quickly Special Report: Argenica Therapeutics now has a clear path forward to clear the clinical hold currently in place on its investigational new drug application that will enable clinical trials for its lead drug ARG-007. In its full letter, the US Food and Drug Administration (FDA) requested additional information to provide assurance that proposed dosing for a US trial of ARG-007 in acute ischaemic stroke can be achieved safely in humans. The FDA has also requested that Argenica Therapeutics (ASX:AGN) conduct three additional in vitro cell culture studies with clinical research organisations to address identified gaps in data. AGN plans to use safety data from its Phase 2 acute ischaemic stroke trial, which will be available in September, as part of its response to the FDA's request for safety assurance. It adds that three additional studies are small ones that can be completed quickly and build on existing data it has already generated. 'We are pleased to have received the clarification from the FDA as to the additional information required to progress the IND application,' managing director Dr Liz Dallimore said. 'Importantly from a timing and cost perspective, the requested additional in vitro assays are standard assays which are straightforward and efficient to perform. 'Argenica will work with the FDA to ensure the proposed approach to providing the additional information is adequate to lift the clinical hold.' Preventing brain injury During acute neurological events such as stroke, traumatic brain injury (TBI), and hypoxic brain damage, around 1.9 million brain cells die for every minute that blood flow is halted. AGN's ARG-007 is a synthetic peptide designed to protect brain cells from dying in the critical minutes and hours by protecting brain tissue during and after these events. The company noted it was targeting acute ischaemic stroke as many patients that experienced it had a thrombectomy, where a radiologist inserts a catheter through the wrist or groin and guides it up into the brain to physically remove a clot. However, this process has the risk of reperfusion injury, which occurs when blood flow rapidly returns to previously oxygen-deprived brain tissue after a clot is removed and potentially causes additional damage. Dosing of patients in a double-blinded, randomised, placebo-controlled Phase 2 trial of ARG-007 in acute ischaemic stroke patients was completed in April. This involved 92 patients presenting to eight emergency departments around Australia with data-read out due in September with safety the main endpoint. The secondary endpoint for the trial will examine efficacy, with a brain scan taken 48 hours post administration of either the placebo or ARG-007. ARG-007 would be the first neuroprotective drug on the global market if approved, tapping into a large addressable global market for stroke and potentially other indications. The global stroke management market was valued at $36.1 billion in 2022, and is projected to reach $74 bn by 2032, driven by several factors including a growing ageing population. There are more than 45,000 strokes annually in Australia and 795,000 in the US – the world's largest healthcare markets. This article was developed in collaboration with Argenica Therapeutics, a Stockhead advertiser at the time of publishing. This article does not constitute financial product advice. You should consider obtaining independent advice before making any financial decisions.

The Australian
9 hours ago
- The Australian
Cadillac set to name their first-ever F1 driver as they turn to unemployed six-time Grand Prix winner, 35, to lead team
Sergio Perez is edging closer to signing a deal with new F1 side Cadillac. The General Motors-backed team will make its debut on the grid in 2026 and are yet to announce their line up. Mexican driver Perez has not been in the paddock this season after he was axed by Red Bull last December. Fox Sports, available on Kayo Sports, is the only place to watch every practice, qualifying session and race in the 2025 FIA Formula One World Championship™ LIVE in 4K. New to Kayo? Join now and get your first month for just $1. But talks are ramping up with Cadillac and a deal could be announced in the coming weeks. Perez's Red Bull exit came after a run of woeful results where he failed to make a podium in his final 19 races. Sergio Perez had Daniel Ricciardo snapping at his heels while the Aussie was driving for Visa Cash App RB. (Photo by) In April, Perez made it clear he had spoken to a handful of teams and said: 'We are talking to a few parties out there. 'Once I know all my options, I will make a decision. What is very clear to me is that I'm only coming back if the project makes sense, and it's something I can enjoy.' Perez is a hot prospect given he is a six-time race winner and brings strong commercial appeal in Mexico. Mexican driver Sergio Perez struggled in his final years at Red Bull. (Photo by Andrej ISAKOVIC / AFP) The 35-year-old is also backed by Mexican billionaire Carlos Slim. Perez has reportedly held talks with Alpine with Franco Colapinto struggling to hit the ground running. Mercedes reserve driver Valtteri Bottas is said to be a favourite for the other Cadillac seat. Michael Schumacher's son Mick was also considered by the American team, having been out of F1 for three-years.